Corporate Profile

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey.

Learn More

Minimum 15 minutes delayed. Source: LSEG

Latest News

I-Mab to Participate at the Piper Sandler Healthcare Conference

2024.11.21

The 36 th Annual Healthcare Conference will be held in New York , December 3-5, 2024 ROCKVILLE, Md. , Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S. -based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the

I-Mab Reports Third Quarter 2024 Results

2024.11.14

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027,

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

2024.11.06

ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S. -based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu , PhD, MBA has been appointed
View All

Recent Events

View All

Investor Presentation